Alessandro Sanna
YOU?
Author Swipe
View article: Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia
Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia Open
Introduction Continuous treatment with a Bruton's tyrosine kinase inhibitor (BTKi) is a standard of care option for patients (pts) with previously untreated chronic lymphocytic leukemia (CLL). Ibrutinib (Ibr), the first-in-class BTKi, has …
View article: Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study
Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study Open
Background. Clinical trials have documented the efficacy of ibrutinib in combination with venetoclax in CLL. Indeed, Ibrutinib plus venetoclax (I+V) is the first all oral fixed duration treatment approved for treatment naive patients with …
View article: Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice Open
The concept of fitness for novel agents in chronic lymphocytic leukemia (CLL) remains debated. Comorbidities and treatment-related logistics are increasingly recognized as key factors in treatment feasibility. Venetoclax-obinutuzumab (VO) …
View article: Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study
Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study Open
Familial chronic lymphocytic leukemia (CLL) constitutes 5% to 7% of CLL and has previously shown a more aggressive pattern of evolution than sporadic CLL, even if no difference in overall survival (OS) has been observed. This multicenter c…
View article: Characteristics of Tonsillopharyngitis Patients at Ibnu Sina Hospital Makassar from January 2023 to May 2024
Characteristics of Tonsillopharyngitis Patients at Ibnu Sina Hospital Makassar from January 2023 to May 2024 Open
Background: Upper respiratory tract infections in children often lead to tonsillopharyngitis, which is caused by viruses (such as adenovirus and rhinovirus) or bacteria, especially Group A beta-hemolytic streptococcus (GABHS). Predisposing…
View article: Characteristics of Chemotherapy Side Effects in Patients with Nasopharyngeal Cancer
Characteristics of Chemotherapy Side Effects in Patients with Nasopharyngeal Cancer Open
This study investigates the characteristics of post-chemotherapy side effects in patients with nasopharyngeal cancer at Dr. Wahidin Sudirohusodo Hospital in Makassar during 2023. Utilizing secondary data, the research analyzes the prevalen…
View article: BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Open
Background: Patients (pts) with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who relapse after treatment with covalent Bruton tyrosine kinase inhibitors (cBTKi) have limited effective treatment options. Pirtobrutinib i…
View article: Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi
Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi Open
Patients with chronic lymphocytic leukemia (CLL) or indolent B-cell non-Hodgkin lymphoma (iB-NHL) are at risk of developing severe COVID-19 infection, with a high mortality rate in the pre-vaccination era (18%-30%). These patients respond …
View article: Management of infections for patient treated with ibrutinib in clinical practice
Management of infections for patient treated with ibrutinib in clinical practice Open
Ibrutinib, a highly effective inhibitor of the Bruton tyrosine kinase, has significantly transformed the therapeutic approach in chronic lymphocytic leukemia (CLL). Despite these advancements, the disease continues to be characterized by i…
View article: Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study Open
Real-world data in clinical practice are needed to confirm the efficacy and safety that ibrutinib has demonstrated in clinical trials of patients with chronic lymphocytic leukemia (CLL). We described the real-world persistence rate, patter…
View article: Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine
Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine Open
Background Oral formulations ofhypomethylating agents decitabine (ASTX727) and azacitidine (cc-486, AZA) were approved respectively for treatment of higher risk myelodysplastic syndromes (HR-MDS) and for maintenance of acute myeloid leukem…
View article: A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial
A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial Open
In recent years the management of patients (pts) with chronic lymphocytic leukemia (CLL) has benefited from a deeper knowledge of the mechanisms underlying the disease and from the development of novel therapeutic approaches. That notwiths…
View article: Kinetics of Lymphocytosis during First-Line Treatment with BTK Covalent Inhibitors in Chronic Lymphocytic Leukemia Patients: An Italian Multicenter Experience of Real Life
Kinetics of Lymphocytosis during First-Line Treatment with BTK Covalent Inhibitors in Chronic Lymphocytic Leukemia Patients: An Italian Multicenter Experience of Real Life Open
CONCLUSIONS In chronic lymphocytic leukemia (CLL) patients (pts) the first phase of treatment with covalent Bruton's tyrosine kinase inhibitors (cBTKi), Ibrutinib or Acalabrutinib, is characterized by an increased absolute lymphocyte count…
View article: Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study
Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study Open
Introduction. Infections are a major source of morbidity and mortality in patients with Chronic Lymphocytic Leukemia (CLL). The development of targeted agents decreased the rate of these complications in comparison to standard chemoimmunot…
View article: Impact of COVID-19 in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Possible Role of the Association to Anti-CD20 Antibody? a Multicentre Seifem Study
Impact of COVID-19 in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Possible Role of the Association to Anti-CD20 Antibody? a Multicentre Seifem Study Open
Introduction. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for coronavirus disease 19 (COVID-19), has led to a significant increase of morbidity worldwide. A recent meta-analysis showed a high case fatality rat…
View article: P1509: CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PREVIOUS INFECTIONS HAD IMPACT ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH VENETOCLAX: A MULTICENTRE SEIFEM STUDY
P1509: CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PREVIOUS INFECTIONS HAD IMPACT ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH VENETOCLAX: A MULTICENTRE SEIFEM STUDY Open
Topic: 30. Infections in hematology (incl. supportive care/therapy) Background: Infections are a major source of morbidity and mortality in patients with Chronic Lymphocytic Leukemia (CLL). The development of targeted agents decreased the …
View article: PB1942: PARTIAL RESPONSE WITH LYMPHOCYTOSIS (PR-L) IS NOT APPLICABLE FOR ACALABRUTINIB. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
PB1942: PARTIAL RESPONSE WITH LYMPHOCYTOSIS (PR-L) IS NOT APPLICABLE FOR ACALABRUTINIB. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE. Open
Topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical Background: Increased absolute lymphocyte count (ALC) characterizes chronic lymphocytic leukemia (CLL), and it is also observed in the first phase of treatment with Ib…
View article: Supplementary Tables 1-6 from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients
Supplementary Tables 1-6 from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients Open
PDF file - 54K, MFI values indicating basal and EPO and G-CSF induced activation of ERK1/2, STAT5, p38 MAPK, and caspase-3 in MDS subpopulations. Correlation between EPO response in vitro and in the clinic
View article: Supplementary Figure 5 from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients
Supplementary Figure 5 from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients Open
PDF file - 48K, Flow cytometric analysis of STAT5 activation after G-CSF and EPO stimulation
View article: Data from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients
Data from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients Open
Purpose: Myelodysplastic syndromes (MDS) are heterogeneous clonal diseases characterized by cytopenias as a result of ineffective hematopoiesis. Little is known about alterations in signal transduction pathways in MDS.Experimental Design: …
View article: Supplementary Figure 1 from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients
Supplementary Figure 1 from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients Open
PDF file - 58K, Basal activation of P-ERK1/2, P-STAT5, P-p38 MAPK, and cleaved caspase-3 in CD34+ MDS and normal cells
View article: Data from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients
Data from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients Open
Purpose: Myelodysplastic syndromes (MDS) are heterogeneous clonal diseases characterized by cytopenias as a result of ineffective hematopoiesis. Little is known about alterations in signal transduction pathways in MDS.Experimental Design: …
View article: Supplementary Figure 1 from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients
Supplementary Figure 1 from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients Open
PDF file - 58K, Basal activation of P-ERK1/2, P-STAT5, P-p38 MAPK, and cleaved caspase-3 in CD34+ MDS and normal cells
View article: Supplementary Tables 1-6 from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients
Supplementary Tables 1-6 from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients Open
PDF file - 54K, MFI values indicating basal and EPO and G-CSF induced activation of ERK1/2, STAT5, p38 MAPK, and caspase-3 in MDS subpopulations. Correlation between EPO response in vitro and in the clinic
View article: Supplementary Figure 6 from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients
Supplementary Figure 6 from Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients Open
PDF file - 101K, Full-length immunoblots of ERK1/2 activation before and after TPA treatment in Kasumi-1 cells and ERK1/2 activation before and after TPA and EPO treatment in normal BMMC. Original graphic indicating a correlation between t…